Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
22.01.2025 07:44:55
|
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
This article Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases originally appeared on Benzinga.com.Weiter zum vollständigen Artikel bei Benzinga

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
Analysen zu Eli Lillymehr Analysen
20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Ai Holdings Corp | 2 706,00 | 0,11% |
|
Alphabet Inc (A) Cert Deposito Arg Repr 0.034482 Shs | 6 560,00 | -1,20% |
|
Alphabet A (ex Google) | 208,65 | -0,41% |
|
Alphabet C (ex Google) | 208,95 | -0,12% |
|
Eli Lilly | 715,30 | 2,07% |
|
Novartis AG ADR Cert. Deposito Arg. Repr. 0.5 ADRs | 50 725,00 | -1,93% |
|
Novartis AG 2. Linie | 106,18 | 1,76% |
|
Novartis AG (Spons. ADRS) | 112,50 | 1,35% |
|
Novartis AG | 112,60 | 1,76% |
|